Synthesis and evaluation of human phosphodiesterases (PDE) 5 inhibitor analogs as trypanosomal PDE inhibitors. 1. Sildenafil analogs
Synthesis and evaluation of human phosphodiesterases (PDE) 5 inhibitor analogs as trypanosomal PDE inhibitors. 1. Sildenafil analogs
Date
2012-01
Authors
Wang, Cuihua
Ashton, Trent D.
Gustafson, Alden
Bland, Nicholas D.
Ochiana, Stefan O.
Campbell, Robert K.
Pollastri, Michael P.
Ashton, Trent D.
Gustafson, Alden
Bland, Nicholas D.
Ochiana, Stefan O.
Campbell, Robert K.
Pollastri, Michael P.
Linked Authors
Person
Person
Person
Person
Person
Alternative Title
Citable URI
As Published
Date Created
Location
DOI
Related Materials
Replaces
Replaced By
Keywords
Neglected disease
Trypanosoma brucei
Target repurposing
Phosphodiesterase inhibitors
TbrPDEB1
PDE5
Sildenafil
Trypanosoma brucei
Target repurposing
Phosphodiesterase inhibitors
TbrPDEB1
PDE5
Sildenafil
Abstract
Parasitic diseases, such as African sleeping sickness, have a significant impact on the health and well-being in the poorest regions of the world. Pragmatic drug discovery efforts are needed to find new therapeutic agents. In this report we describe target repurposing efforts focused on trypanosomal phosphodiesterases. We outline the synthesis and biological evaluation of analogs of sildenafil (1), a human PDE5 inhibitor, for activities against trypanosomal PDEB1 (TbrPDEB1). We find that, while low potency analogs can be prepared, this chemical class is a sub-optimal starting point for further development of TbrPDE inhibitors.
Description
Author Posting. © The Author(s), 2012. This is the author's version of the work. It is posted here by permission of Elsevier B.V. for personal use, not for redistribution. The definitive version was published in Bioorganic & Medicinal Chemistry Letters 22 (2012): 2579-2581, doi:10.1016/j.bmcl.2012.01.119.